The growth drivers for Wockhardt’s European business include exports, new product launches, penetration in the European Union through mutual recognition, and strategic acquisitions.

Wockhardt’s European presence consists of Wockhardt UK in the United Kingdom, Esparma GmbH in Germany, Pinewood in Ireland and Negma in France. The Company has made five international acquisitions and has effectively integrated and synergised their operations. Wockhardt acquired UK-based companies -- Wallis Laboratory in 1998 and CP Pharmaceuticals in 2003, expanding business into Europe. In 2004, Wockhardt acquired esparma GmbH, which signalled its entry into the German market and the larger European Union. In the year 2006 Pinewood was acquired in Ireland strengthening its presence in the European market. Wockhardt staying very aggressive on the growth through the inorganic route has acquired Negma in France which provided a strong entry and foothold into the French market with foray into branded business.

Wockhardt UK Limited

Wockhardt UK Limited is amongst the 10 largest generics companies in UK and the second largest hospital generics supplier. The Company has a comprehensive, FDA-approved manufacturing facility for injectables. This facility plays a strategic role in the company’s growth plans in --

Driving growth through partnerships in contract manufacturing (Wockhardt UK has entered into a product development and contract manufacturing relationship with Amylin Inc. for Exenatide). Being a manufacturing base for Europe.

Wockhardt UK has built up a critical mass in the segments of

Retail Generics, Hospital Generics, Private Label GSL / OTC Pharmaceuticals, Dental Care (denture cleaning tablets, powders and fixative creams).

Wockhardt UK’s oral healthcare products are sold both as own (ConfiDent brand) and private label to a large number of European retailers such as --- Boots, Superdrug, Sainsbury, ASDA, Morrisons (UK), Kruidvat, Delhaize, VIP, Aldi, and Redwin (Global).

Wockhardt UK has comprehensive US FDA approved manufacturing capabilities for injectables such as cartridges, vials and ampoules (including lyophilized products).

Given its resources, it is not surprising that Wockhardt UK is the partner of choice for reputed international companies for manufacturing and marketing.

For more information on Wockhardt UK, click here >> www.wockhardt.co.uk
Kindly email us at contactuk@wockhardt.com

Pinewood Ireland

Pinewood is the largest and fastest growing generic pharmaceutical company in Ireland with a strong presence in the pharmaceutical and renal business. Established in 1976, it has over 200 prescription and over-the-counter products in the market. Since October 2006, it is part of pharmaceutical and biotechnology major Wockhardt Ltd. The company currently employs about 360 people in Ireland.

Pinewood’s market leadership in Ireland is driven by its ability to more than 98% of Ireland's pharmacies and 100% of Irish wholesalers. The marketing team covers over 2500 general practitioners. Pinewood has a successful track record of Day 1 product launches and gaining highest market share. About half of the Top 10 products in home pharma have been launched in last 2 years. Pinewood is also the market leader in renal business in Ireland with close to 60% market share.

Pinewood has a large manufacturing facility in Tipperary focusing on creams, liquids, powders and sachets. These products primarily cater to UK and other European markets. Pinewood also exports to New Zealand, Afghanistan and various countries in Africa. The facility is also used by large transnational organizations like Pfizer, Sandoz, etc. for sourcing their products.

The Company is committed to continuous growth and has demonstrated its competence both in Ireland and various international markets. At Pinewood, there is constant endeavor towards strong and sustainable value creation.  The company has an impressive product offering both for the Ireland and international market. Pinewood is fully geared to grow its leadership in Ireland market and exploit innovative prospects in its global operations across geographies and business areas.

For more information on Pinewood click here >> www.pinewood.ie
Kindly email us at info@pinewood.ie

Negma, France

NEGMA is the 4th largest independent pharmaceutical company in France. It is a fully integrated pharmaceutical Group mastering the various stages of the life cycle of its products from R&D, API manufacturing, to manufacturing, conditioning and packaging of final products, and finally the promotion to prescribers and distribution to wholesalers and pharmacies.

Negma is headquartered in Toussus-le-Noble, Paris. It operates 2 manufacturing facilities located in Quimper and Nevers. It has rich IPR portfolio consisting of 172 patents.

The main products of NEGMA hold leading positions in their respective therapeutic classes in the French pharmaceutical market:

Osteoarthritis / Rheumatology (ART 50® / Zondar®, molecule: Diacerein),

Arterial Hypertension and CHF (Nébilox®, molecule: Nebivolol),

Phlebotonic / Vasculoprotector (Veinamitol® / Rhéoflux® / Troxérutine Mazal® molecule: Troxerutin).

The Group’s products, which benefit from excellent doctors and patients recognition, are sold in all pharmacies in the French territory. Negma has in-house promotion networks comprised of 230 medical representatives covering the entirety of the French territory. This enables the company to maintain close relationships with prescribers and the French medical community, and to ensure, with the support of the marketing department, the most efficient promotion of its diversified and balanced portfolio of products.